Serum Adiponectin Levels In Patients Research Articles

Study of adiponectin gene (rs1501299) polymorphism and serum adiponectin level in patients with primary knee osteoarthritis

BackgroundWe aimed to study, for the first time in the Egyptian population, the relationship between the serum adiponectin level in knee osteoarthritis (KOA) patients and its correlation with clinical, radiological, and ultrasonographic characteristics. Additionally, investigate the relationship between the adiponectin (ADIPOQ) gene rs1501299 (+ 276G/T) polymorphism and KOA susceptibility and severity.MethodsThis case-control study enrolled 40 patients with primary KOA and 40 matched controls. All patients underwent physical examination of the knee, pain assessment using the visual analogue scale (VAS), and functional evaluation by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Severity of KOA was assessed by Kellgren Lawrence (KL) grading scale and ultrasonography grading systems. Serum adiponectin levels and adiponectin (ADIPOQ) gene single nucleotide polymorphism (SNP) (rs1501299) genotyping were done for all patients and controls.ResultsThe study included 40 patients with primary symptomatic KOA and 40 controls with comparable age, sex, and body mass index. The genotype of the rs1501299 (+ 276G/T) polymorphism of the ADIPOQ gene was determined using TaqMan allelic discrimination. An enzyme-linked immunosorbent test was used to measure the level of serum adiponectin. The Western Ontario and McMaster Universities Osteoarthritis (WOMAC) score was used to assess functional capability, while the visual analogue scale was utilised to assess knee pain. Using the Kellgren-Lawrence (KL) grading method and global femoral cartilage (GFC) ultrasound grading, the severity of KOA was assessed. No significant differences between patients and controls as regards the genotype distributions and allele frequencies (p = 0.400, p = 0.507, respectively) of ADIPOQ gene rs1501299 (+ 276G/T) polymorphism. Furthermore, serum adiponectin level was significantly higher in the patients compared to healthy subjects (p < 0.001). Additionally, adiponectin level had a significant negative correlation with disease severity as evaluated by KL and GFC grading (r=-0.351, p = 0.027 and r=-0.397, p = 0.011, respectively).ConclusionsThe ADIPOQ gene rs1501299 (+ 276G/T) polymorphism was not associated with KOA severity or vulnerability. The level of adiponectin considerably reduced as the severity of KOA rose, indicating that adiponectin may have a preventive effect in KOA.

Serum Adiponectin Predicts COVID-19 Severity.

Adiponectin is primarily known for its protective role in metabolic diseases, and it also possesses immunoregulatory properties. Elevated levels of adiponectin have been observed in various inflammatory diseases. However, studies investigating adiponectin levels in the serum of COVID-19 patients have yielded conflicting results. This study aimed to assess serum adiponectin levels in 26 healthy controls, as well as in 64 patients with moderate and 60 patients with severe COVID-19, to determine a potential association between serum adiponectin and the severity of COVID-19. Serum adiponectin levels in severe COVID-19 patients were significantly lower than in those with moderate disease and healthy controls, who exhibited similar serum adiponectin levels. Among patients with moderate disease, positive correlations were observed between serum adiponectin and C-reactive protein levels. Of note, serum adiponectin levels of severe COVID-19 cases were comparable between patients with and without dialysis or vasopressor therapy. Superinfection with bacteria did not exert a notable influence on serum adiponectin levels in patients with severe disease. Patients who were diagnosed with severe COVID-19 and vancomycin-resistant enterococci bacteremia showed a significant reduction in their serum adiponectin levels. An analysis conducted on the entire cohort, including both moderate and severe COVID-19 patients, showed that individuals who did not survive had lower serum adiponectin levels when compared to those who survived. In summary, this study highlights a decrease in serum adiponectin levels in severe COVID-19 cases, indicating the potential utility of adiponectin as an additional biomarker for monitoring disease severity in COVID-19 or critical illnesses in general.

Internal mechanism of correlation between angiotensin II gene and serum adiponectin level in patients with cerebrovascular complications of H-type hypertension.

The study aimed to explore the correlation between the angiotensin II (Ang II) gene and serum adiponectin expression in patients with cerebrovascular complications of H-type hypertension (HH) and its mechanism. A total of 50 cases of outpatient patients in Tianjin Fourth Central Hospital were recruited from January 2022 to June 2023 and rolled into three groups according to their blood pressure and basic information, namely the HH cerebrovascular complications group, the non-H-type hypertension (NHH) group, and the healthy control (HC) group. Peripheral blood samples were taken; one sample was utilized to test for the Ang II gene and the methylation of Ang II, and the other sample was utilized to measure serum adiponectin levels to analyze the relationship between serum adiponectin level and Ang II in patients with cerebrovascular complications of HH. The ratio of male to female was 8:7 in the group of cerebrovascular complications of HH, and mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 167.34 mm Hg and 112.56 mm Hg, respectively. In the NHH group, the mean SBP was 165.89 mm Hg, and the mean DBP was 113.47 mm Hg. The blood pressure of the HC group was in the normal range. The Ang II content was the highest in the group with cerebrovascular complications of HH, followed by the group with NHH, and the lowest in the HC group. Pyrosequencing chart of patients with cerebrovascular complications of HH showed that the content of deoxyphosphate ribose G was the highest, while the content of A was the highest in NHH patients. Moreover, the serum adiponectin level of patients with HH and NHH was superior to that of the HC group, and the adiponectin level between the former two groups and the HC group differed considerably. Ang II levels were high in patients with cerebrovascular complications of HH and were positively correlated with adiponectin levels. The incidence of cerebrovascular complications of HH may be related to Ang II levels in patients.

Changes of Serum Adiponectin Level in Patients with Obstructive Sleep Apnea Hypopnea Syndrome and Its Relationship with Sleep Monitoring Indexes.

To observe the changes of serum adiponectin (AP) levels in patients with obstructive sleep apnea hypopnea syndrome (OSAHS) and explore the correlation between serum AP and polysomnography (PSG) parameters in patients with OSAHS. The data of subjects who underwent PSG at the hospital between January 2021 and December 2022 were collected retrospectively and divided into simple snoring group (AHI < 5 times/h, n = 45), mild OSAHS group (5 ≤ AHI < 15 times/h, n = 63), moderate OSAHS group (15 ≤ AHI ≤ 30 times/h, n = 52), and severe OSAHS group (AHI > 30 times/h, n = 60). The general data, PSG indices, and serological indices of the subjects were collected and compared between groups. Pearson correlation analysis and partial correlation analysis were employed to examine the correlation between serum AP level and PSG parameters. Ordered logistic regression was employed to analyze the risk factors influencing the severity of OSAHS. The predictive capability of the serum AP level in determining the occurrence of OSAHS was assessed using ROC. The serum AP levels of subjects with different subtypes of PSG indicators were compared. In the simple snoring group, mild OSAHS group, moderate OSAHS group, and severe OSAHS group, there were statistically significant differences in microarousal count, MAI, AHI, times of blood oxygen decreased by ≥ 3%, L-SaO2, and TS90% among the 4 groups (P < 0.05). The level of serum AP was positively correlated with L-SaO2 and negatively correlated with the proportion of REM, microarousal count, MAI, AHI, times of blood oxygen decreased by ≥ 3%, TS90%, and LP (P < 0.05). High AHI was a risk factor affecting the severity of OSAHS (95% CI: 1.446-4.170). The AUC of serum AP level in diagnosing OSAHS was 0.906 (95% CI: 0.8601-0.9521), and when the Youden Index was 0.678, the sensitivity was 88.9%, and the specificity was 78.9% (P < 0.0001). In the population with a high microarousal count, high AHI, and high times of blood oxygen decreased by ≥ 3% and high TS90%, the serum AP level was lower than that in the low-level population (P < 0.05). In the population with high L-SaO2, the serum AP level was higher than that in low-level population (P < 0.05). The level of serum AP decreased with the increase of the disease severity of patients with OSAHS and demonstrates a significant predictive capability for the occurrence of OSAHS. Monitoring the level of serum AP can effectively forecast the risk of OSAHS. Furthermore, alterations in serum AP levels are associated with both hypoxemia and a heightened frequency of arousal in patients with OSAHS.

Evaluation of Lipid Profile and Serum Adiponectin Levels in Patients with Lichen Planus.

The Article Abstract is not available.

A Study of Serum Adiponectin Levels in Patients with Polycystic Ovarian Syndrome and its Correlation with Various Cardiometabolic Risk Markers.

Polycystic ovarian syndrome (PCOS) is the most common metabolic disorder in the reproductive age group, the pathogenesis of which is constantly evolving with the discovery of novel molecules and the lookout for potential therapeutic targets. The aim of the present study was to estimate the circulating levels of serum adiponectin in patients with PCOS compared to controls and to find its correlation with markers of cardiovascular risk, with special emphasis on circulating levels of oxidised low-density lipoprotein (oxLDL). In this cross-sectional observational study recently diagnosed, PCOS subjects were compared with age- and body mass index (BMI)-matched controls. All the included subjects underwent detailed clinical, biochemical and hormonal evaluation, including lipid profile, 75 g oral glucose tolerance test, fasting serum insulin, fasting serum adiponectin, oxLDL, total testosterone and anti-Mullerian hormone. Appropriate statistical methods were performed using SPSS (version 21) and Microsoft Excel (2019). A total of 56 PCOS cases and 32 controls were included in the study. Mean values of serum adiponectin (μg/mL) in our study were found to be significantly lower in PCOS cases (11.53 ± 4.74) versus controls (14.73 ± 5.61) irrespective of BMI. Mean values of serum oxLDL (μg/dL) were found to be higher in PCOS cases (157.96 ± 53.89) versus controls (117.52 ± 45.44), with a significant negative correlation between adiponectin and oxLDL in cases. No difference in levels of adiponectin was found between the different PCOS phenotypes. Hypoadiponectinaemia was found to be associated with PCOS irrespective of obesity in PCOS subjects. Serum oxLDL can complement adiponectin as early predictor of CV risk in PCOS.

The effects of N-acetylcysteine administration on metabolic status and serum adiponectin levels in patients with metabolic syndrome: A randomized, double-blind, placebo-controlled trial

• NAC administration to patients with MetS improved antioxidative defense system and inflammatory status. • NAC administration to patients with MetS ameliorated glycemic control and serum HDL-cholesterol levels. • NAC prescription may be a new strategy for the amelioration of metabolic parameters in patients with MetS. This study examined the impact of N-acetylcysteine (NAC) administration on metabolic parameters and serum adiponectin levels in individuals with metabolic syndrome (MetS). This randomized clinical trial included 76 people with MetS, aged 25–75 years. Participants were randomly assigned to receive either 1800 mg/day NAC (n = 38) or matched placebo (n = 38) for 12 weeks. Fasting blood samples were collected at the onset and at the end of 12-week intervention to quantify metabolic parameters. NAC significantly reduced fasting plasma glucose (P = 0.02), fasting serum insulin (P = 0.006), insulin resistance index (P = 0.005), and serum C-reactive protein (P = 0.003), and increased serum HDL-cholesterol (P = 0.001) and plasma total glutathione (P < 0.001) versus the placebo group. NAC administration did not alter adiponectin, blood pressure, other lipid indices, malondialdehyde, and total antioxidant capacity. Overall, 1800 mg/day NAC consumption for 12 weeks in MetS subjects had positive impacts on the parameters of glycemic homeostasis, HDL-cholesterol, inflammatory status, and body antioxidative defense system. NAC prescription may be a new strategy for the amelioration of metabolic parameters in individuals with MetS. Clinical Trial Registration: This clinical trial was prospectively registered in the Iranian website for registration of clinical trials ( https://www.irct.ir/trial/44284 ).

Serum Adiponectin Levels In Patients Of Type 2 Diabetes Mellitus

Aim: To find out the serum adiponectin levels in patients of type 2 diabetes and non diabetics. Methods: A cross-sectional, comparative study included 88 subjects. Out of 88 cases, 68 were diagnosed cases of T2DM. In 68 diagnosed cases, 34 were newly diagnosed cases of T2DM without any treatment and 34 were on oral hypoglycemic medicine. 20 subjects were controls which were age and sex matched. Serum adiponectin levels were estimated by using ELISA procedure. Total cases were divided into Group A: 34 newly diagnosed patients of T2DM without any treatment. Group B: 34 patients of T2DM on oral hypoglycemic medicine and Group C: 20 subjects of normal controls. Results: In our study, mean  SD values of adiponectin levels in non-diabetics in Group C were 1560 1044.6 ng/ml. In group A, mean  SD values of adiponectin levels were 1153±792.6ng/ml and in group B, mean  SD values of adiponectin levels were 1601±1210.5ng/ml. The adiponectin levels were lower in diabetics without medication (A) as compared to the control group (C). The difference was statistically significant between groups A vs B and A vs C while the difference was statistically non significant between groups B vs C. Conclusion: The adiponectin levels were lower in diabetics without medication (group A) as compared to the diabetics with drugs (group B) and control group (C). The difference was statistically significant between groups A vs B and A vs C while the difference was statistically insignificant between groups B vs C. Keywords: Adiponectin level, Lipids, Type-2 diabetes mellitus

The Effect of Positive İnotropic Therapy on Serum Adiponectin Level in Patients with Acute Decompensated Heart Failure

The Effect of Positive İnotropic Therapy on Serum Adiponectin Level in Patients with Acute Decompensated Heart Failure

Serum Adiponectin Level in Patients with Psoriasis and its Correlation with the Clinical Severity

Background: Psoriasis is a common chronic immune mediated papulosquamous disease that affects 2-3% of the population. The exact cause of psoriasis is still unclear, but it is considered a disease of dysregulated inflammation which is driven and maintained by interaction among multiple components of immune system in genetically predisposed individuals. Adipose tissue is an active endocrine organ contributing to the regulation of multiple metabolic pathways via self-produced bioactive products called adipokine. Adiponectin of adipose origin has the highest circulating concentration among the known adipokines. Adiponectin regulates skin inflammation especially IL-17-related psoriasiform dermatitis. Objective: This study was aimedto estimate the serum level of Adiponectin and detect its correlation with activity of psoriatic patients. Patients and Methods: This case control study included a total of 50 patients with psoriasis and 50 healthy individuals, attending at Outpatient Clinic, Department of Dermatology, Venereology and Andrology in collaboration with Department of Clinical Pathology, Faculty of Medicine, Zagazig University Hospitals. This study was conducted between November 2019 to November 2020. Psoriasis severity was classified according to psoriatic area and severity index (PASI) score. Serum level of adiponectin was determined by ELISA for both groups. Results: The results revealed that control group had significantly higher level of adiponectin than psoriasis patients. There was a negative significant correlation between adiponectin and Psoriasis Area and Severity Index (PASI score) (p <0.001**). Sensitivity of adiponectin in diagnosis of psoriasis was 94%, specificity was 90% and accuracy was 92%. Conclusion: Adiponectin measurement in serum of patients with psoriasis provides a tool for monitoring disease activity.

Distribution of serum adiponectin isoforms in pediatric patients with steroid-sensitive nephrotic syndrome

BackgroundSerum adiponectin circulates in three multimeric isoforms: high-molecular-weight (HMW), middle-molecular-weight (MMW), and low-molecular-weight (LMW) isoforms. Potential change in the circulating adiponectin levels in patients with nephrotic syndrome (NS) remain unknown. This study aimed to assess the levels of total adiponectin and the distribution of its isoforms in pediatric patients with NS.MethodsWe sequentially measured total adiponectin and each adiponectin isoform levels at the onset of NS, initial remission, and during the remission period of the disease in 31 NS patients. We also calculated the ratios of HMW (%HMW), MMW (%MMW), and LMW (%LMW) to total adiponectin incuding 51 control subjects.ResultsThe median of total serum adiponectin levels in patients were 36.7, 36.7, and 20.2 μg/mL at the onset, at initial remission, and during the remission period of NS, respectively. These values were significantly higher than those in control subjects. The median values of %HMW, %MMW, and %LMW values were 56.9/27.0/14.1 at the onset, 62.0/21.8/13.4 at the initial remission, and 58.1/21.7/17.5 at during the remission period of NS, respectively. Compared with control subjects, %HMW at initial remission and %MMW at the onset were high, and the %LMW values at the onset and at initial remission were low.ConclusionsIn patients with NS, total serum adiponectin levels increase at the onset of the disease, and the ratio of adiponectin isoforms changes during the course of the disease. Further studies are needed to delineate the mechanisms between proteinuria and adiponectin isoforms change.

Can improvements in sleep quality positively affect serum adiponectin-levels in patients with obstructive sleep apnea?

BackgroundAssess if changes in sleep quality (Sleep Quality Index, SQI) based on cardiopulmonary coupling-analysis (CPC) impacts serum adiponectin-levels in patients with cardiovascular disease (CVD). MethodsSecondary analysis of electrocardiogram (ECG) data from the Heart Biomarker Evaluation in Apnea Treatment study (HeartBEAT), a multicenter, controlled trial in patients with CVD and moderate-severe sleep apnea, randomly assigned to intervention of Continuous Positive Airway Pressure (CPAP), Nocturnal Supplemental Oxygen (NSO) or Healthy Lifestyle and Sleep Hygiene Education (HLSE; control group). Participants with good-quality ECG-signal (n = 241) were included. ResultsImproving CPC-sleep quality was associated with net average improvements in serum adiponectin-levels 2.69 μg/ml (p = 0.005) irrespective of therapy initiated. After controlling for confounders, a unit increase in SQI was associated with increase in serum adiponectin-levels 0.071 μg/ml (p = 0.012) and decrease in insulin-levels 0.197 μIU/ml (p = 0.0018). Similarly, a percentage point increase in sleep apnea indicator (SAI) was associated with decrease in serum adiponectin-levels of 0.071 μg/ml (p = 0.017) and increase in insulin-levels of 0.218 μIU/ml (p = 0.020). A percentage point increase in CPC-sleep fragmentation (eLFCBB) had a predicted increase in glucose-levels 0.371 mg/dl (p = 0.009) and insulin-levels 0.284 μIU/ml (p = 0.010).In patients receiving CPAP-therapy, a difference in serum adiponictin levels of 3.82 μg/ml (p = 0.025) is observed comparing patients in which SQI-improved to patients that SQI-declined during the study period. The difference is mostly due to a decrease in serum adiponectin levels in patients that decline in SQI (−3.20 μg/ml). ConclusionImprovements in sleep quality were associated with higher serum adiponectin-levels, and improved measures of glycemic metabolism which may have beneficial effects on metabolic syndrome and cardiovascular health. Clinical trial registration name and numberThe Heart Biomarker Evaluation in Apnea Treatment (HeartBEAT) study is registered at https://clinicaltrials.gov/ct2/show/NCT01086800.

Assessment of serum adiponectin levels in patients with type 1 diabetes and chronic kidney disease

Assessment of serum adiponectin levels in patients with type 1 diabetes and chronic kidney disease

Adiponectin and Sarcopenia: A Systematic Review With Meta-Analysis.

BackgroundSarcopenia is a progressive loss of skeletal muscle mass whose pathophysiology has been proposed to possibly involve mechanisms of altered inflammatory status and endocrine function. Adiponectin has been shown to modulate inflammatory status and muscle metabolism. However, the possible association between adiponectin levels and sarcopenia is poorly understood. In order to fill this gap, in the present manuscript we aimed to summarize the current evidence with a systematic review and a meta-analysis of studies reporting serum adiponectin levels in patients with sarcopenia compared to non-sarcopenic controls.MethodsAn electronic search through Medline/PubMed, Cochrane Library, and Science Direct was performed till March 1, 2020. From the included papers, meta-analysis of cross-sectional studies comparing serum levels of adiponectin between patients with sarcopenia and controls was performed.ResultsOut of 1,370 initial studies, seven studies were meta-analyzed. Sarcopenic participants had significantly higher levels of adiponectin Hedges’ g with 95% confidence interval (CI): 1.20 (0.19–2.22), p = 0.02 than controls. Subgroup analysis, performed in Asian population and focused on identification of the condition based on AWGS criteria, reported higher adiponectin levels in sarcopenic population (2.1 (0.17–4.03), p = 0.03 and I2 = 98.98%. Meta-regression analysis revealed female gender to significantly influence the results as demonstrated by beta = 0.14 (95% CI (0.010–0.280), p = 0.040).ConclusionsOur meta-analysis found evidence that sarcopenia is associated with higher adiponectin levels. However, caution is warranted on the interpretation of these findings, and future longitudinal research is required to disentangle and better understand the topic.

Liver and serum adiponectin levels in non‐alcoholic fatty liver disease

Adiponectin is an adipokine that has anti-steatotic, anti-inflammatory and anti-fibrotic effects. The impact of these different activities impact on the development and progression of non-alcoholic fatty liver disease (NAFLD) is not well understood. The aim of this study was to evaluate both liver and serum adiponectin levels in patients with and without NAFLD and determine any clinical correlations. Liver tissue and serum samples were collected from patients undergoing liver biopsy between April 2014 and July 2020, and categorized based on histopathological diagnosis into hepatic steatosis (HS), non-alcoholic steatohepatitis (NASH), and hepatitis control (HC). A Luminex xMAP assay was performed on both liver and serum samples to measure adiponectin levels. Statistical analysis compared liver adiponectin (LA) and serum adiponectin (SA) levels between groups. A total of 48 participants were included in the analysis. The mean LA level was lowest in the HS group, followed by the NASH group and the HC group (P = 0.036). The mean SA level was 3.61 μg/mL for the NAFLD group and was significantly lower than that in the HC (7.51 μg/mL; P = 0.001). Adiponectin levels are lower in NAFLD compared to HC in both serum and liver tissue. LA levels in patients with HS were significantly lower than in both the NASH and HC groups, suggesting that adiponectin is related to inflammation in the liver and probably reflects its role in the pathogenesis of NAFLD.

Study of serum adiponectin levels for early detection of type 2 diabetes mellitus and its complications on kidney

Background: Type 2 diabetes mellitus is a chronic metabolic disorder due to insulin resistance caused by destruction of beta cells of pancreas. Insulin resistance in newly diagnosed type 2 diabetes mellitus patients leads to hyperglycemia. Serum adiponectin is a more sensitive and specific biomarker for early detection of diabetic nephropathy than urinary microalbuminuria.Methods: This is a case-control study conducted in Akash Institute of Medical Sciences, A total 180 subjects (120 cases and 60 controls). All the subjects included after informed consent, blood samples and urine samples are collected from the all the subjects. The serum Adiponectin and was estimated by using enzyme-linked immunoassay (ELISA) and fasting blood sugar (FBS), post prandial blood sugar (PPBS) and renal function test (RFT) was also estimated by laboratory standard methods.Results: This study was evaluated the FBS, PPBS, RFT and serum adiponectin levels in patients with type 2 diabetes mellitus patients and compare them with healthy controls. The serum adiponectin levels more significantly elevated in newly diagnosed type 2 diabetes mellitus patients and compared with the healthy controls. The study also found that significantly elevated levels of FBS, PPBS and RFT in type 2 diabetes mellitus patients and compared with the healthy controls, The statistically significant levels of serum adiponectin in patients with type 2 diabetes mellitus and when compared with the controls (p= 0.0001).Conclusions: The study suggesting that the s estimation of serum adiponectin levels in newly diagnosed type 2 diabetes mellitus patients useful for early detection of diabetic nephropathy. Because elevated levels of serum adiponectin in patients with newly diagnosed type 2 diabetes mellitus, this levels are positively correlated with the FBS and PPBS.

Study of the Role of Adiponectin Gene Polymorphism in Patients with Thyroid Disorders

Background: Both hypo & hyperthyroidism are associated with some morbidity & mortality. Adiponectin is a fat cell-derived hormone that protect against atherosclerotic cardiovascular diseases through its enhancing effect on insulin sensitivity. Clinical studies investigating serum adiponectin levels in patients with hypothyroidism and hyperthyroidism have reported conflicting results. Objective: The study aimed to study the role of adiponectin gene polymorphism in patients with thyroid disorders either hypothyroidism or hyperthyroidism. Also, the relation of adiponectin gene polymorphism with obesity and DM. Patients and Methods: Cross sectional study was conducted on one hundred and fifty cases that were classified into hypothyroid group and hyperthyroid group. History, examination and investigation (adiponectin gene) was done. Results: In current study within hypothyroid & hyperthyroid group, there was non-significant relation between gene polymorphism and either total T3, free T3, free T4 or TSH. There was statistically non-significant relation between associated diabetes and either gene or allele polymorphism among patients within hypothyroid group and hyperthyroid group. There was statistically non-significant relation between patient BMI and either gene or allele polymorphism among patients within hypothyroid group and hyperthyroid group. Conclusion: There was no role of adiponectin gene polymorphism and either total T3, free T3, free T4 or TSH. In addition, there was no role of adiponectin gene polymorphism and either obesity and DM.

Study of the Role of Adiponectin Gene Polymorphism in Patients with Thyroid Disorders

Background: Both hypo & hyperthyroidism are associated with some morbidity & mortality. Adiponectin is a fat cell-derived hormone that protect against atherosclerotic cardiovascular diseases through its enhancing effect on insulin sensitivity. Clinical studies investigating serum adiponectin levels in patients with hypothyroidism and hyperthyroidism have reported conflicting results. Objective: The study aimed to study the role of adiponectin gene polymorphism in patients with thyroid disorders either hypothyroidism or hyperthyroidism. Also, the relation of adiponectin gene polymorphism with obesity and DM. Patients and Methods: Cross sectional study was conducted on one hundred and fifty cases that were classified into hypothyroid group and hyperthyroid group. History, examination and investigation (adiponectin gene) was done. Results: In current study within hypothyroid & hyperthyroid group, there was non-significant relation between gene polymorphism and either total T3, free T3, free T4 or TSH. There was statistically non-significant relation between associated diabetes and either gene or allele polymorphism among patients within hypothyroid group and hyperthyroid group. There was statistically non-significant relation between patient BMI and either gene or allele polymorphism among patients within hypothyroid group and hyperthyroid group. Conclusion: There was no role of adiponectin gene polymorphism and either total T3, free T3, free T4 or TSH. In addition, there was no role of adiponectin gene polymorphism and either obesity and DM.

Serum Adiponectin Level in Patients with Systemic Lupus Erythematosus and its Correlation with Disease Activity

Background: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disorder characterised by widespread inflammation of connective tissues affecting the skin, joints, kidneys, heart, lungs, and nervous system. SLE is associated with significant morbidity, thus requiring prompt evaluation, appropriate therapy and long-term follow-up. Objective: This study was performed to measure serum adiponectin in SLE patients and to correlate it with SLEDAI and to evaluate its role as a biomarker of activity in SLE patients specially renal in the hope of preventing or at least postponing renal damage. Patients and methods: This study included 72 subjects, 36 patients and 36 volunteers. The patients were divided into three groups. Group I (active renal) 12 patients having renal disease activity, group II (active non-renal) 12 patients having non-renal disease activity and group III (inactive SLE). 36 apparently healthy volunteers were included (group IV) as a control group. Results: A highly significant difference in serum adiponectin between SLE groups and control group. A highly significant positive correlation between serum adiponectin and 24 h protein in urine. Negative correlation between serum adiponectin and C3 & C4. A significant difference between SLE groups as regards serum anti-double stranded DNA titres, which were higher in renal group patients, also C3 & C4 levels which were lower in the renal group. Serum adiponectin level was not correlated with SLE Disease Activity Index (DAI). Conclusion: Adiponectin level was strongly associated with active SLE with renal disease. Adiponectin level in SLE patients was not correlated with SLEDAI. It may be a promising biomarker for prediction of renal activity of SLE.

Serum Adiponectin Level in Patients with Systemic Lupus Erythematosus and its Correlation with Disease Activity

Background: Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disorder characterised by widespread inflammation of connective tissues affecting the skin, joints, kidneys, heart, lungs, and nervous system. SLE is associated with significant morbidity, thus requiring prompt evaluation, appropriate therapy and long-term follow-up. Objective: This study was performed to measure serum adiponectin in SLE patients and to correlate it with SLEDAI and to evaluate its role as a biomarker of activity in SLE patients specially renal in the hope of preventing or at least postponing renal damage. Patients and methods: This study included 72 subjects, 36 patients and 36 volunteers. The patients were divided into three groups. Group I (active renal) 12 patients having renal disease activity, group II (active non-renal) 12 patients having non-renal disease activity and group III (inactive SLE). 36 apparently healthy volunteers were included (group IV) as a control group. Results: A highly significant difference in serum adiponectin between SLE groups and control group. A highly significant positive correlation between serum adiponectin and 24 h protein in urine. Negative correlation between serum adiponectin and C3 & C4. A significant difference between SLE groups as regards serum anti-double stranded DNA titres, which were higher in renal group patients, also C3 & C4 levels which were lower in the renal group. Serum adiponectin level was not correlated with SLE Disease Activity Index (DAI). Conclusion: Adiponectin level was strongly associated with active SLE with renal disease. Adiponectin level in SLE patients was not correlated with SLEDAI. It may be a promising biomarker for prediction of renal activity of SLE.